ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

ElevateBio launches with $150 million for cell and gene therapies

by Ryan Cross
May 18, 2019 | APPEARED IN VOLUME 97, ISSUE 20

ElevateBio, a cell- and gene-therapy holding company based in Cambridge, Massachusetts, has launched with $150 million in series A financing from MPM Capital and other private investors. ElevateBio will offer R&D and cGMP manufacturing facilities to be shared across several portfolio companies, each with a different disease focus. The company was founded to break some of the bottlenecks that are particularly problematic for cell- and gene-therapy start-ups.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment